Leadership

We have assembled a highly qualified management team with broad and deep oncology and biotech experience to execute on our mission to develop novel precision oncology therapies based on synthetic lethality.

Management

Lloyd M. Segal

President & CEO

Lloyd M. Segal has served as our President and CEO and as a member of our board of directors since our incorporation in September 2016. From 2010 to 2016, he was a Managing Partner with Persistence Capital Partners, a Canadian-based healthcare private equity investor. Previously, Mr. Segal was a consultant with McKinsey & Company, and served as CEO of several emerging biotechnology companies including Advanced Bioconcept Inc., Caprion Pharmaceuticals Inc. (now CellCarta), which he co-founded, and Thallion Pharmaceuticals Inc.

He serves as a member of the board of directors of GBC American Fund, a U.S. growth-focused mutual fund and of Aktis Oncology, a private developer of oncology radiopharmaceuticals. Mr. Segal also previously served as Chairman of LMC Diabetes & Endocrinology, Canada’s leading national endocrinology practice. From 2016 to 2020, Mr. Segal served as Entrepreneur-in-Residence with Versant Ventures. He was honored in 2013 by the Financial Times as Outstanding Director of the Year for public companies and also previously served on the boards of directors of several public and private U.S. and Canadian companies.

Mr. Segal received a B.A. in politics from Brandeis University and an M.B.A. from Harvard Business School.

Steve Forte

EVP, Chief Financial Officer

Steve Forte has served as our Executive Vice President, Chief Financial Officer since October 2019. Prior to joining us, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc. from August 2018 through June 2019, during which time Clementia was acquired by Ipsen S.A. From September 2015 to August 2018, Mr. Forte served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments.

From September 2014 to September 2015, he served as Executive Director of Finance of CST Canada Co. From 2005 to 2014, Mr. Forte held positions of increasing responsibility at Aptalis Pharma Inc., including most recently holding the position of Vice President, Financial Reporting where he was responsible for the overall corporate controllership function of the company.

Mr. Forte received a Bachelor of Commerce in accountancy from Concordia University and is a Certified Professional Accountant in the Province of Québec and a Certified Information Systems Auditor (non-practicing) with ISACA.

Philip Herman

EVP, Commercial & New Product Development

Phillip Herman has served as our Executive Vice President, Commercial & New Product Development since January 2022. Mr. Herman brings extensive commercial experience with a focus in oncology and rare diseases and has a proven track record of product launches across a broad spectrum of therapeutic areas.

Mr. Herman most recently served as the Chief Commercial Officer of Y-mAbs Therapeutics where he led the successful launch and commercialization of DANYELZA® (naxitamab). He served in this role from June 2018 to December 2021. Prior to Y-mAbs, Mr. Herman held various commercial and marketing positions including VP, Head of Santhera U.S. and Head of Commercial, Head of Marketing at Dyax, Director of Marketing at Vanda Pharmaceuticals, and various positions of increasing responsibility at Pfizer Inc.

Mr. Herman received a B.A. in business administration from Baldwin Wallace University, and an M.B.A. from the Kellogg School of Management at Northwestern University.

Maria Koehler, M.D., Ph.D.

EVP & Chief Medical Officer

Maria Koehler, M.D., Ph.D. has served as our Executive Vice President, Chief Medical Officer since May 2019. Prior to joining us, from September 2017 to April 2019, Dr. Koehler served as the Chief Medical Officer of Bicycle Therapeutics Limited. From March 2009 to September 2017, Dr. Koehler served as Vice President in Oncology Reserarch and Development, most recently as VP of Strategy, Innovation and Collaborations for the Oncology Business Unit at Pfizer Inc. Prior to joining Pfizer, Dr. Koehler was the group leader for the Medicine Development Center of GlaxoSmithKline Oncology.

Prior to that, Dr. Koehler was a Senior Medical Director for oncology research and development at AstraZeneca plc. Dr. Koehler has also served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh as well as the director of the Bone Marrow Transplant Program and associate professor at St. Christopher’s Hospital in Philadelphia. Dr. Koehler serves as an independent director on the boards of directors of Ikena Therapeutics and Silverback Therapeutics.

Dr. Koehler is a board-certified hematology/oncology physician. Dr. Koehler received an M.D. and Ph.D. from Silesian School of Medicine in Katowice, Poland.

Michael Zinda, Ph.D.

EVP, Chief Scientific Officer

Michael Zinda, Ph.D. has served as our Executive Vice President, Chief Scientific Officer since May 2019 and previously served as Executive Vice President, Head of Research and Development of our U.S. subsidiary, Repare Therapeutics USA Inc., from June 2017 to May 2019. Prior to joining us, he spent 16 years at AstraZeneca from 2001 to May 2017, where he obtained the position of Executive Director, Head of Cancer Bioscience.

In this role, Dr. Zinda served on the global science leadership team, oncology research board and the Acerta research and early development teams accountable for strategy, key collaborations/partnerships and delivery of an innovative portfolio of patient-centric drug discovery programs.

Dr. Zinda received a B.Sc. in biology from Minnesota State University Moorhead and a Ph.D. in molecular biology from Vanderbilt University. He received his post-doctoral training at Princeton University and Eli Lilly & Company.

Cameron Black, Ph.D.

EVP, Discovery

Cameron Black, Ph.D. has served as our Executive Vice President, Discovery since June 2016. Prior to joining us, Dr. Black co-founded Kanyr Pharma in 2013 and Kaneq Pharma in 2010 to develop drugs targeting cancer and metabolic disease, respectively. Prior to that, he spent nearly two decades at the Merck Frosst Center for Therapeutic Research, where he was responsible for the identification of seven drug candidates.

He led both the discovery and early clinical development of the cathepsin K inhibitor, odanacatib, a once-weekly treatment for osteoporosis. In 2010, he was made Site Scientific Operations Lead, responsible for the objectives and staffing of all discovery programs at Merck Frosst.

Dr. Black received a B.Sc. in chemistry from the University of Saskatchewan and a Ph.D. in chemistry from Harvard University.

Kim Seth, Ph.D.

EVP, Chief Business Officer

Kim Seth, Ph.D. has served as our Executive Vice President, Chief Business Officer since June 2017. Prior to joining us, from July 2015 to May 2017, he served as Chief Business Officer, and Chief Operating Officer at Resilience Therapeutics, Inc., where he was a co-founder and member of the Board of Directors. From February 2014 to January 2015, Dr. Seth served as Senior Vice President and Chief Business Officer at Epirus Pharmaceuticals, Inc., and from January 2011 to February 2014, he served as Executive Director, Worldwide R&D, at Pfizer Inc., where he held both global operational and strategy leadership positions.

In his role as Head, External Strategy & Innovation at Pfizer, Dr. Seth led strategic initiatives to enter and expand into new markets, including leading the strategy development and operational launch of Pfizer’s integrated Immuno-Oncology platform. As Head, Research Investments, he helped lead the design and execution of Pfizer’s R&D operational turnaround. Prior to joining Pfizer, Dr. Seth was Vice President at Goldman Sachs, where he was an investment research analyst covering global large-cap and specialty pharmaceuticals sectors.

Dr. Seth received an A.B. cum laude in economics from Harvard College and a Ph.D. in neurobiology from Harvard University.

Founders

Daniel Durocher, Ph.D.

Daniel Durocher, Ph.D., is a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute where he acts as Director of the Biomedical Program. He is also a Full Professor in the Department of Molecular Genetics at the University of Toronto. Dr. Durocher’s overarching interest lies in understanding how cells maintain genome integrity, with an emphasis on the detection, signaling and repair of DNA double-strand breaks. Dr. Durocher is widely recognized for his use of functional genomics approaches to study the DNA damage response, and those efforts established ubiquitin as a key organizing molecule in DNA damage repair. Among the awards received by Dr. Durocher in recent years, particularly notable is the 2015 Paul Marks Prize for cancer research awarded by Memorial Sloan Kettering. In 2010, he was also named one of Canada’s Top 40 under 40, a prize that highlights exceptional contributions to Canadian society by individuals under 40 years of age in the arts, science and business spheres. Dr. Durocher received a B.Sc. from Université de Montréal, a Ph.D. from McGill University and he did his postdoctoral training at the University of Cambridge, UK.

Agnel Sfeir, Ph.D.

Agnel Sfeir, Ph.D., is the Paine Webber Chair in Cancer Genetics at Sloan Kettering Institute and a full member of Memorial Sloan Kettering Cancer Center (MSKCC). She is also a Professor at Weill Cornell Medicine Graduate School of Medical Sciences. Her research focuses on how mammalian cells maintain genome stability. Her lab made important contributions to our understanding of DNA double-strand break repair, telomere maintenance, and mitochondrial DNA replication and repair. She is the recipient of numerous accolades, including the NIH director’s new innovator award, Pew-Stewart scholarship for cancer research, Damon Runyon-Rachleff innovator award, Mathers foundation, V-Foundation scholar grant, Pershing Square-Sohn cancer research alliance prize, and an innovator award from The David and Lucile Packard Foundation. Dr. Agnel Sfeir received a B.S and M.Sc. in biology from the American University of Beirut and a Ph.D. in Cell Biology from the University of Texas Southwestern Medical Center. She received her post-doctoral training at the Rockefeller University in the lab of Professor Titia de Lange. Prior to joining MSKCC in 2021, Dr. Sfeir was the Skirball Associate Professor of Genetics in the Skirball Institute of Biomolecular Medicine at NYU School of Medicine.

Frank Sicheri, Ph.D.

Frank Sicheri, Ph.D., is a Senior Investigator at the Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital and Professor in the Departments of Molecular Genetics and Biochemistry at the University of Toronto. His research focuses on the structural biology of eukaryotic signaling with specific interests in the protein kinase superfamily and the ubiquitin proteolytic system. His lab made important contributions to understanding normal signaling mechanisms, mechanisms of dysregulation that contribute to disease, and mechanisms of drug action and resistance. He is the recipient of numerous awards and honours including election as a Royal Society of Canada Fellow, the Merck Frosst Prize, Canada Research Chair in Signal Transduction, and Terry Fox Young Investigator Scholar. Dr. Frank Sicheri received a B.Sc. and Ph.D. in biochemistry from McMaster University. He received his post-doctoral training at Rockefeller University under the mentorship of Dr. John Kuriyan.
Board of Directors

Thomas Civik

Thomas Civik has served as Chair of our board of directors since September 2021. Mr. Civik most recently served as President and Chief Executive Officer of Five Prime Therapeutics until its acquisition by Amgen for $1.9 billion in April 2021. He was previously Chief Commercial Officer at Foundation Medicine, delivering significant growth during his tenure and launching the first ever FDA-approved pan-cancer comprehensive genomic test. He held various roles over a 17-year career at Genentech, including responsibility for several important therapies such as Avastin, Tecentriq, Alecensa and Tarceva. He currently serves on the board of directors of Pyxis Oncology Inc. Mr. Civik received a B.A. from St. Norbert College, and an M.B.A. from Northwestern University Kellogg School of Management.

David Bonita, M.D.

David Bonita, M.D. has served as a member of our board of directors since September 2019. Dr. Bonita is a member of OrbiMed Advisors LLC, an investment firm, where he has held various positions since joining in June 2004. He currently serves on the boards of directors of Tricida, Inc. and Imara Inc. Dr. Bonita previously served on the boards of directors of several other public and private companies, including Ambit Biosciences Corporation, Clementia Pharmaceuticals Inc., Loxo Oncology, Inc., SI-BONE, Inc. and ViewRay Inc. Prior to joining OrbiMed, he worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. Dr. Bonita has published scientific articles in peer-reviewed journals based on signal transduction research performed at Harvard Medical School. Dr. Bonita received a B.A. in biology from Harvard University and a joint M.D./M.B.A. from Columbia University.

Jerel Davis, Ph.D.

Jerel Davis, Ph.D. has served as a member of our board of directors since our incorporation in September 2016. He has been at Versant Venture Management, LLC, a healthcare investment firm, where he has held the position of managing director since 2015. He has played a critical role in Versant’s company creation strategies and has served on the boards of directors of many public and private biotech companies including BlueRock Therapeutics, Turnstone Biologics, Chinook Therapeutics, Inception 5 and Northern Biologics. Prior to joining Versant, Dr. Davis was an associate principal at McKinsey & Company in various healthcare markets including the United States, Canada, Europe and China. Dr. Davis received a B.S. in mathematics and biology from Pepperdine University and a Ph.D. in population genetics from Stanford University.

Sam Kulkarni

Samarth Kulkarni, Ph.D. has served as a member of our board of directors since November 2019. Dr. Kulkarni is the Chief Executive Officer of CRISPR Therapeutics AG, a position he has held since 2017. He initially joined CRISPR in August 2015 as Chief Business Officer, and then served as CRISPR’s President and Chief Business Officer from May 2017 to November 2017. Prior to joining CRISPR, Dr. Kulkarni was a partner within the pharmaceuticals and biotechnology practice at McKinsey & Company, a global consulting firm, where he held various positions of increasing responsibility after joining in 2006. He also serves on the board of directors of Black Diamond Therapeutics, Inc. Dr. Kulkarni received a Ph.D. in bioengineering and nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology.

Todd Foley

Todd Foley has served as a member of our board of directors since June 2017. Since 1999, Mr. Foley has worked at MPM Capital LLC, a healthcare-focused venture capital firm, where he currently serves as a Managing Director focusing on investments in biotech companies. He currently serves on the board of directors of Chiasma, Inc. and Rhythm Pharmaceuticals, Inc. and also serves as on the boards of directors of several other privately-held life sciences and pharmaceutical companies. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an M.B.A from Harvard Business School.

Briggs W. Morrison, M.D.

Briggs Morrison, M.D. has served as a member of our board of directors since June 2017. Dr. Morrison currently serves as the President, Head of R+D at Syndax Pharmaceuticals, Inc., where he has been since June 2015, and as a member of its board of directors since July 2015. Prior to joining Syndax, Dr. Morrison served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc from January 2012 to June 2015, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. From October 2007 to December 2011, Dr. Morrison held a number of positions of increasing responsibility at Pfizer Inc., culminating in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business. Dr. Morrison served as chairman of the board of TransCelerate BioPharma Inc. from 2014 to 2015, a member of the executive committee of the Clinical Trials Transformation Initiative sponsored by FDA. In addition to Syndax, Dr. Morrison currently serves on the boards of directors of two other public companies, Arvinas, Inc. and Werewolf, Inc. as well as on the boards of directors of several private companies. He is also currently an executive partner at MPM Capital LLC, a healthcare-focused venture capital firm, a position he has held since June 2015. Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut Medical School. He completed residency training in internal medicine at Massachusetts General Hospital and a fellowship in medical oncology at the Dana-Farber Cancer Institute.

Ann D. Rhoads

Ann Rhoads has served as a member of our board of directors since June 2020. Ms. Rhoads most recently served as Chief Financial Officer of Forty Seven, Inc. (acquired by Gilead Sciences, Inc.), a position she held from March 2018 until its sale to Gilead in 2020. Previously, from 2010 to January 2017, Ms. Rhoads was Executive Vice President and Chief Financial Officer of Zogenix, Inc. From 1998 through 2009, Ms. Rhoads was at Premier, Inc., serving as Vice President, Strategic Initiatives from 1998 to 2000 before serving as Chief Financial Officer from 2000 through 2009. Ms. Rhoads currently serves on the board of directors of Globus Medical Inc. and Evoke Pharma, Inc., and she previously served on the board of directors of Iridex Corporation and Novellus Systems, Inc. Ms. Rhoads received a B.S. in finance from the University of Arkansas and an M.B.A. from the Harvard Graduate Business School.

Carol Schafer

Carol Schafer has served as a member of our board of directors since March 2019. Ms. Schafer is currently a consultant in the biotech industry and has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the biopharmaceutical sector. From April 2007 to September 2018, she held various positions of increasing responsibility at Wells Fargo Securities, most recently serving as Vice Chair, Equity Capital Markets. From December 2003 to February 2007, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals. Prior to that, Ms. Schafer worked at J.P. Morgan, where she held positions of increasing responsibility, most recently serving as a managing director in equity capital markets. Ms. Schafer currently serves on the boards of directors of Idera Pharmaceuticals, Inc. and Five Prime Therapeutics, Inc. Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University.

Lloyd M. Segal

Lloyd M. Segal has served as our President and CEO and as a member of our board of directors since our incorporation in September 2016. From 2010 to 2016, he was a Managing Partner with Persistence Capital Partners, a Canadian-based healthcare private equity investor. Previously, Mr. Segal was a consultant with McKinsey & Company, and served as CEO of several emerging biotechnology companies including Advanced Bioconcept Inc., Caprion Pharmaceuticals Inc. (now CellCarta), which he co-founded, and Thallion Pharmaceuticals Inc. He serves as a member of the board of directors of GBC American Fund, a U.S. growth-focused mutual fund and of Aktis Oncology, a private developer of oncology radiopharmaceuticals. Mr. Segal also previously served as Chairman of LMC Diabetes & Endocrinology, Canada’s leading national endocrinology practice. From 2016 to 2020, Mr. Segal served as Entrepreneur-in-Residence with Versant Ventures. He was honored in 2013 by the Financial Times as Outstanding Director of the Year for public companies and also previously served on the boards of directors of several public and private U.S. and Canadian companies. Mr. Segal received a B.A. in politics from Brandeis University and an M.B.A. from Harvard Business School.

Collaborate with us and let’s change the world.